Go Pro
NASDAQ:PTIX

Atrinsic Q1 2025 Earnings Report

Atrinsic logo
$0.22 -0.04 (-14.99%)
As of 08/6/2026 02:22 PM Eastern

Atrinsic EPS Results

Actual EPS
-$2.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Q1 2025
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Tuesday, August 18, 2026, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Atrinsic (NASDAQ:PTIX) Stock Price Up 14.5% - Still a Buy?
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
Protagenic Therapeutics swaps warrants for shares
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile